FDA’s requirement for truthful, balanced risk and benefit information applies to drugmakers, leaving a loophole for both ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

(Reuters) -Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months ...